Gain Therapeutics, Inc. (GANX)

NASDAQ: GANX · IEX Real-Time Price · USD

3.150

-0.030 (-0.94%)

At close: Apr 18, 2024, 4:00 PM

3.100

-0.050 (-1.59%)

After-hours: Apr 18, 2024, 4:32 PM EDT

Gain Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Revenue	0.06	0.14	0.16	0.03	0.04	0.02
Revenue Growth (YoY)	-60.62%	-15.08%	471.29%	-30.07%	100.40%	-
Gross Profit	0.06	0.14	0.16	0.03	0.04	0.02
Selling, General & Admin	10.79	9.54	6.83	1.25	0.56	0.22
Research & Development	11.52	8.38	7.16	2.26	1.59	0.83
Operating Expenses	22.31	17.92	13.99	3.51	2.14	1.05
Operating Income	-22.25	-17.78	-13.83	-3.48	-2.1	-1.03
Interest Expense / Income	0	0	0	0	0.02	0.05
Other Expense / Income	-0.06	-0.28	0.06	0.09	0.07	0.01
Pretax Income	-22.19	-17.5	-13.89	-3.57	-2.19	-1.1
Income Tax	0.08	0.09	0	0.01	0.01	0.01
Net Income	-22.27	-17.59	-13.89	-3.58	-2.19	-1.11
Shares Outstanding (Basic)	13	12	10	3	2	2
Shares Outstanding (Diluted)	13	12	10	3	2	2
Shares Change	9.49%	16.90%	279.11%	19.17%	-	-
EPS (Basic)	-1.71	-1.48	-1.37	-1.33	-0.97	-0.49
EPS (Diluted)	-1.71	-1.48	-1.37	-1.33	-0.97	-0.49
Free Cash Flow	-18.88	-14.81	-12.46	-3.26	-1.88	-0.75
Free Cash Flow Per Share	-1.45	-1.25	-1.23	-1.22	-0.84	-0.33
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-40328.26%	-12688.10%	-8379.80%	-12047.54%	-5084.89%	-4989.66%
Profit Margin	-40354.33%	-12555.13%	-8418.86%	-12387.67%	-5310.88%	-5364.36%
Free Cash Flow Margin	-34217.53%	-10571.20%	-7551.72%	-11291.38%	-4557.35%	-3651.32%
EBITDA	-22.1	-17.43	-13.87	-3.56	-2.16	-1.04
EBITDA Margin	-40059.20%	-12442.97%	-8407.04%	-12335.81%	-5237.69%	-5058.67%
Depreciation & Amortization	0.08	0.06	0.02	0.01	0	0
EBIT	-22.19	-17.5	-13.89	-3.57	-2.17	-1.04
EBIT Margin	-40210.67%	-12488.77%	-8416.43%	-12369.02%	-5243.92%	-5062.26%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).